ViaNautis: Funding, Investors & Team (Sep 2026)
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the guidance of CEO and serial entrepreneur, Dr Francesca Crawford. The main goal of the company is to harness the unique capabilities of the groundbreaking polyNaut® technology. PolyNaut® is an adaptable nano-engineered polymer technology that is specifically designed for precise intracellular delivery. This innovative technology allows polymer nanoparticles to transport a wide range of substances, from small molecules to genetic materials, creating what is referred to as a "bionic nanoparticle." The flexible structure of polyNaut® can be customized to encapsulate numerous types of genetic payloads, surpassing current standards for both viral and non-viral delivery. Notably, it improves the effectiveness of the encapsulated substances by directly delivering them to the cell cytoplasm, facilitated by GOTO® technology for intracellular shuttling. PolyNaut® distinguishes itself from traditional non-viral delivery methods through its exceptional ability to target specific cells and overcome biological barriers, including the challenging blood-brain barrier. When modified for central nervous system (CNS) delivery through transcytosis, polyNaut® nanoparticles demonstrate exceptional uptake in the brain. By utilizing the advanced polyNaut® platform, ViaNautis is at the forefront of developing innovative therapies for CNS diseases and cystic fibrosis. The company is actively creating a portfolio of treatments and collaborating with reputable pharmaceutical and biotech companies to unlock the potential of promising genetic molecules and therapeutic platforms.
ViaNautis has raised $47.8M across 2 funding rounds on record, the most recent an undisclosed round of $23.3M announced in Sep 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ViaNautis Company Profile and Key Stats
Latest funding round on record: Sep 2026.
ViaNautis Funding Rounds
ViaNautis raised $24.5M in a Series A announced in Nov 2023.
2.8 years later, an undisclosed round of $23.3M was announced in Sep 2026.
ViaNautis Investors
14 investors are recorded in total; the 5 named above are those the record identifies.
ViaNautis Founders and Leadership Team
Contact details for the ViaNautis team: 2 of 3 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →ViaNautis Funding Compared to Other Biotechnology Startups
ViaNautis' latest round of $23.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ViaNautis in Biotechnology and Cambridge
Companies Similar to ViaNautis
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
ViaNautis Funding FAQs
What does ViaNautis do?
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the guidance of CEO and serial entrepreneur, Dr Francesca Crawford. The main goal of the company is to harness the unique capabilities of the groundbreaking polyNaut® technology. PolyNaut® is an adaptable nano-engineered polymer technology that is specifically designed for precise intracellular delivery. This innovative technology allows polymer nanoparticles to transport a wide range of substances, from small molecules to genetic materials, creating what is referred to as a "bionic nanoparticle." The flexible structure of polyNaut® can be customized to encapsulate numerous types of genetic payloads, surpassing current standards for both viral and non-viral delivery. Notably, it improves the effectiveness of the encapsulated substances by directly delivering them to the cell cytoplasm, facilitated by GOTO® technology for intracellular shuttling. PolyNaut® distinguishes itself from traditional non-viral delivery methods through its exceptional ability to target specific cells and overcome biological barriers, including the challenging blood-brain barrier. When modified for central nervous system (CNS) delivery through transcytosis, polyNaut® nanoparticles demonstrate exceptional uptake in the brain. By utilizing the advanced polyNaut® platform, ViaNautis is at the forefront of developing innovative therapies for CNS diseases and cystic fibrosis. The company is actively creating a portfolio of treatments and collaborating with reputable pharmaceutical and biotech companies to unlock the potential of promising genetic molecules and therapeutic platforms.
How much funding has ViaNautis raised?
ViaNautis has raised $47.8M across 2 rounds on record. The most recent is an undisclosed round of $23.3M announced in Sep 2026.
When did ViaNautis last raise funding?
ViaNautis' most recent funding round on record is an undisclosed round of $23.3M, announced in Sep 2026.
Who has invested in ViaNautis?
Investors on record for ViaNautis include Eli Lilly, 4BIO Capital, Abcam, Cystic Fibrosis Foundation, SCI Ventures. FundedIQ records 14 investors in total.
Who founded ViaNautis?
FundedIQ lists Raffaele Marroccella (Founder) at ViaNautis.
Who is the CEO of ViaNautis?
Adi Hoess is listed as Chief Executive Officer at ViaNautis.
Where is ViaNautis headquartered?
ViaNautis is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does ViaNautis have?
ViaNautis is in the 11-50 employee band.
When was ViaNautis founded?
ViaNautis was founded in 2018.
How does ViaNautis' funding compare to other Biotechnology startups?
ViaNautis' latest round of $23.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's ViaNautis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ViaNautis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.